1,246 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B Buy
Article Searches
Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals http://www.zacks.com/stock/news/342745/bausch-bhc-bids-for-assets-of-synergy-pharmaceuticals?cid=CS-ZC-FT-342745 Dec 13, 2018 - Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.
Allergan plc (AGN) CEO Brenton Saunders Presents at Citi Global Healthcare Conference (Transcript) https://seekingalpha.com/article/4226833-allergan-plc-agn-ceo-brenton-saunders-presents-citi-global-healthcare-conference-transcript?source=feed_sector_healthcare Dec 06, 2018 - Allergan plc (NYSE:AGN) Citi Global Healthcare Conference (Transcript) December 6, 2018, 11:00 AM ET Executives Brenton Saunders - Chairman, President and Chief Executive Officer Analysts Liav Abraham
THW: Global Healthcare Fund With 10%+ Yield https://seekingalpha.com/article/4226785-thw-global-healthcare-fund-10-percent-yield?source=feed_tag_etf_portfolio_strategy Dec 06, 2018 - THW is a Tekla healthcare fund much like THQ, but with an emphasis on holding global securities.THW currently has a quite attractive 10.55% yield.This fund is also showing a discount of 8.29%, but tha
Okta (OKTA) Q3 Earnings and Revenues Surpass Estimates http://www.zacks.com/stock/news/341624/okta-okta-q3-earnings-and-revenues-surpass-estimates?cid=CS-ZC-FT-341624 Dec 06, 2018 - Okta's (OKTA) third-quarter fiscal 2019 results benefit from increasing adoption of the company's Identity solutions.
UBS Global Wealth Management to include environmental scores on its funds in 2019 https://www.cnbc.com/2018/12/03/ubs-global-wealth-management-to-includeenvironmental-scores-on-funds.html Dec 03, 2018 - UBS Global Wealth Management says the new assessments of equity and bond funds will include pollution, ethics and climate change.
Viking Therapeutics Won't Live Up To The Hype https://seekingalpha.com/article/4222613-viking-therapeutics-live-hype?source=feed_all_articles Nov 26, 2018 - VK-2809 has neither clinical data nor an IND in NASH and its development lags 2.5 - 3 years behind MGL-3196.Even if successful in a NASH trial, VK-2809 will be competing in a crowded space with variou
Hedge funds are in a 'vicious downward cycle' as their favorite stocks badly trail market https://www.cnbc.com/2018/11/21/hedge-funds-are-in-a-vicious-downward-cycle-as-their-favorite-stocks-trail.html Nov 21, 2018 - A collection of hedge funds' favorite stock picks — including Facebook, Alibaba and Amazon — is underperforming the broader equity market in the second half of 2018.
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz http://www.zacks.com/stock/news/338827/fda-accepts-allergans-agn-snda-for-anti-infective-avycaz?cid=CS-ZC-FT-338827 Nov 21, 2018 - The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Is Allergan (AGN) a Great Stock for Value Investors? http://www.zacks.com/stock/news/338321/is-allergan-agn-a-great-stock-for-value-investors?cid=CS-ZC-FT-338321 Nov 19, 2018 - Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.
Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space https://seekingalpha.com/article/4221859-alder-biopharmaceuticals-pure-play-migraine-prevention-treatment-crowded-space?source=feed_sector_healthcare Nov 13, 2018 - Alder migraine prevention treatment eptinezumab shows a promising profile in Phase III studies.Alder intends to file a biologic license application (BLA) in Q1 2019. If all goes well, product launch i

Pages: 1234567...125

<Page 2>